NASDAQ:MYOK MyoKardia (MYOK) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MYOK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$224.91▼$224.9150-Day Range$222.81▼$224.9152-Week Range$42.65▼$225.00VolumeN/AAverage Volume752,969 shsMarket Capitalization$11.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get MyoKardia alerts: Email Address Ad Huge AlertsThe #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now! About MyoKardia Stock (NASDAQ:MYOK)MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.Read More Ad Huge AlertsThe #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now! MYOK Stock News HeadlinesApril 11, 2024 | uk.investing.comAstria Therapeutics expands board with new directorApril 9, 2024 | finance.yahoo.comAstria Therapeutics Appoints Sunil Agarwal to Its Board of DirectorsApril 24, 2024 | Huge Alerts (Ad)The #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!March 27, 2024 | seekingalpha.comFULC Fulcrum Therapeutics, Inc.March 16, 2024 | seekingalpha.comCytokinetics: CEO Talks Down Buyout ProspectsFebruary 27, 2024 | uk.finance.yahoo.comQ4 2023 Fulcrum Therapeutics Inc Earnings CallFebruary 27, 2024 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023February 27, 2024 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023April 24, 2024 | Huge Alerts (Ad)The #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!February 16, 2024 | cbsnews.comIf heart disease runs in your family, talk to your doctor about HCMNovember 29, 2023 | finance.yahoo.comBristol Myers pours $100M into RNA drugs for cardiovascular diseasesNovember 29, 2023 | msn.comAvidity and BMS enter $2.3bn deal for cardiovascular targetsNovember 28, 2023 | msn.comWhy Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?November 28, 2023 | msn.comAvidity’s stock rockets on Bristol Myers deal that could mean $2.2 billion in milestone paymentsNovember 22, 2023 | forbes.comHow Viz.ai Uses Artificial Intelligence To Treat Stroke Patients FasterOctober 24, 2023 | benzinga.comWhy LianBio Stock Is Ripping Higher TodayOctober 24, 2023 | msn.comWhy Is LianBio (LIAN) Stock Up 130% Today?October 24, 2023 | msn.comWhy LianBio Stock Is Skyrocketing TodayOctober 24, 2023 | finance.yahoo.comLianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian MarketsOctober 9, 2023 | msn.comBristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 BOctober 4, 2023 | bizjournals.comPeninsula biotech company looks to pump new life into heart disease treatmentsAugust 31, 2023 | msn.comFulcrum Therapeutics (FULC) Price Target Increased by 30.97% to 10.78July 27, 2023 | finance.yahoo.comCutera, Inc. Appoints Taylor Harris as Chief Executive OfficerJuly 27, 2023 | markets.businessinsider.comCutera Names Taylor Harris As CEO, Shares GainJuly 27, 2023 | marketwatch.comCutera Names Taylor Harris CEO, Ending Succession Tussle >CUTRJuly 11, 2023 | finance.yahoo.comAbivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of DirectorsJuly 11, 2023 | markets.businessinsider.comEQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of DirectorsSee More Headlines Receive MYOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOK CUSIPN/A CIK1552451 Webwww.myokardia.com Phone650-741-0900FaxN/AEmployees318Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.99% Return on Assets-42.42% Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio21.03 Sales & Book Value Annual Sales$33.56 million Price / Sales357.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book25.59Miscellaneous Outstanding Shares53,323,000Free FloatN/AMarket Cap$11.99 billion OptionableOptionable Beta1.84 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Tassos Anastasios E. Gianakakos (Age 47)Pres, CEO & Director Comp: $987.02kMr. Taylor C. Harris (Age 44)Chief Financial Officer Comp: $604.47kDr. Robert S. McDowell (Age 62)Chief Scientific Officer Comp: $579.19kMr. Jake B. Bauer (Age 41)Chief Bus. Officer Comp: $547.2kMr. William C. Fairey Jr. (Age 54)Chief Commercial Officer & Exec. VP Comp: $905.02kDr. Leslie LeinwandCo-FounderDr. Christine E. Seidman (Age 67)Co-Founder Dr. Jonathan G. SeidmanCo-FounderDr. James A. Spudich (Age 78)Co-Founder Michelle CorralExec. Director of Corp. Communications & Investor RelationsMore ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYKaruna TherapeuticsNASDAQ:KRTXUnited TherapeuticsNASDAQ:UTHRSarepta TherapeuticsNASDAQ:SRPTBeiGeneNASDAQ:BGNEView All Competitors MYOK Stock Analysis - Frequently Asked Questions How were MyoKardia's earnings last quarter? MyoKardia, Inc. (NASDAQ:MYOK) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.16. What other stocks do shareholders of MyoKardia own? Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), CVS Health (CVS), Gilead Sciences (GILD), AbbVie (ABBV), Walt Disney (DIS), Johnson & Johnson (JNJ), Exelixis (EXEL) and RTX (RTX). This page (NASDAQ:MYOK) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyoKardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
